Cholates for Liver Disease
This trial aims to improve the evaluation of patients with advanced liver disease. Currently, the assessment is limited to imaging, liver function tests, and liver biopsy. However, with advancements in treatments and liver transplantation
Procedure
TIPS Procedure for Liver Cirrhosis and Muscle Loss
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
Contrast Agent
AMRI vs. Ultrasound for Liver Cancer Surveillance
This trial compares the use of gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for the screening and surveillance of subjects with liver cirrhosis who are at risk for developing hepatocellular carcinoma (HCC).
Popular Filters
Trials for Liver Cirrhosis Patients
Endothelin Receptor Antagonist
Zibotentan for Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
"This trial aims to study how the body processes Zibotentan in healthy participants from different ethnic backgrounds, including non-Asian and Japanese individuals."
SGLT2 Inhibitor
Zibotentan + Dapagliflozin for Liver Cirrhosis
This trial is testing a combination of two drugs, zibotentan and dapagliflozin, and also dapagliflozin alone. It targets people with liver disease (cirrhosis) that causes high blood pressure in the liver's veins. The treatment aims to lower this high blood pressure and improve liver health. Dapagliflozin is a medication that has been shown to reduce cardiovascular death and heart failure.
Trials for Idiopathic Pulmonary Fibrosis Patients
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for CFTR Positive Patients
Angiotensin II Receptor Blocker
Losartan for Cystic Fibrosis
This trial is testing losartan, a blood pressure medication, to see if it can help clear mucus from the lungs of cystic fibrosis patients who can't use current treatments. These patients need alternative treatments because they don't respond to existing options. Losartan may reduce lung inflammation, making it easier for them to breathe.
GLP-1 Agonist
GLP-1 Agonist Therapy for Cystic Fibrosis-related Diabetes
This trial looks at whether a weekly injection of a medication called dulaglutide can help improve early-phase insulin secretion and glucose tolerance in people with cystic fibrosis-related diabetes.
Gene Therapy
Gene Therapy (4D-710) for Cystic Fibrosis
This trial is testing a new gene therapy called 4D-710 in adults with cystic fibrosis who can't use standard treatments. The goal is to see if it is safe and effective. 4D-710 is part of a new generation of AAV vectors being developed for cystic fibrosis gene therapy.
Phase 3 Trials
Statin
Simvastatin for Liver Cirrhosis
This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
Galectin Inhibitor
Belapectin for NASH Cirrhosis
This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Thyroid Hormone Receptor Agonist
Resmetirom for NASH Cirrhosis
This trial tests a daily pill called resmetirom for people with a stable form of liver disease not caused by alcohol. The goal is to see if the drug can improve liver function and reduce liver fat, thereby preventing serious complications. Resmetirom has been tested in previous studies for the treatment of liver disease.
Antibiotic
Rifaximin for Hepatic Encephalopathy
This trial tests if rifaximin, an oral antibiotic, can delay brain problems in patients with liver cirrhosis and controlled fluid buildup by reducing harmful gut bacteria. Rifaximin has been shown to reduce the recurrence of brain-related issues and related hospitalizations.
Namodenoson for Liver Cancer
This trial tests an oral medication on patients with advanced liver cancer who have not responded to previous treatments. The goal is to see if this medication can slow down or stop the growth of cancer cells in the liver. The medication is being developed to treat liver cancer, where longer survival was observed in patients with advanced liver disease.
Selective PPAR-delta agonist
Seladelpar for Primary Biliary Cholangitis
This trial is testing Seladelpar, a medication that may help people with a specific liver disease called Primary Biliary Cholangitis (PBC) and early-stage cirrhosis. The drug aims to reduce liver inflammation and damage, potentially improving liver health. Seladelpar has shown promising results in previous studies for PBC, despite initial safety concerns.
Trials With No Placebo
Endothelin Receptor Antagonist
Zibotentan for Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
"This trial aims to study how the body processes Zibotentan in healthy participants from different ethnic backgrounds, including non-Asian and Japanese individuals."
View More Related Trials
Frequently Asked Questions
Introduction to cirrhosis
What are the top hospitals conducting cirrhosis research?
When it comes to advancing the understanding and treatment of cirrhosis, several top hospitals are leading the way with their extensive clinical trial programs. In Pasadena, California Liver Research Institute is making significant strides with five ongoing trials focused specifically on cirrhosis. Since their first recorded cirrhosis trial in 2015, they have shown a commitment to exploring new approaches for this complex condition. Similarly, the University of California San Francisco in San Francisco has been at the forefront of cirrhosis research since 2013 when they initiated their first trial. Currently conducting four active trials, they continue to contribute valuable knowledge to the field.
Meanwhile, across the country in Richmond, Virginia, Hunter Holmes McGuire VA Medical Center is also dedicated to addressing cirrhosis through innovative clinical trials. With a total of 19 completed studies and four ongoing ones aimed at improving outcomes for patients with this liver disease since their initial trial in 2011; they have demonstrated a long-standing commitment to advancing medical knowledge surrounding this condition.
In Baltimore's Mercy Medical Center where twelve past investigations already took place after initially starting from as recent as almost ten years back until 2012; it currently holds an impressive record of managing such cases by having actively running additional four more tests presently underway Meanwhile at Mayo Clinic located Rochester; esteemed institution that can trace its involvement in studying Cirrhosis dating all way back till1997.While there are currently four active clinical trials happening here now,the Mayo Clinic’s cumulative contribution consists of twenty-three previous studies conducted over time.
These renowned institutions demonstrate unwavering dedication not only towards treating those affected by cirrhosis but also furthering our understanding about this complex liver disease impacting millions globally each year.Through these collaborative efforts and pioneering research initiatives we move closer toward improved management strategies enhanced quality-of-life options,and ultimately greater hope for individuals living with or facing potential risk factors associated within Mild-to-severe stages associated Cirrhotic conditions.
Which are the best cities for cirrhosis clinical trials?
Richmond, Virginia; Houston and Dallas, Texas; Seattle, Washington; and New york, New York are among the best cities for cirrhosis clinical trials. Richmond leads with 20 active trials focused on promising treatments such as Rifaximin SSD, belapectin, and Health IT +/- Scheduled Follow Up. Houston and Dallas follow closely behind with 17 ongoing studies examining interventions like Emricasan (5 mg) and LPCN 1148. Seattle and New York also contribute to advancements in cirrhosis research with their respective portfolios of 16 active trials investigating innovative approaches like Semaglutide (SEMA) and Survey-based Patient/Clinician Jumpstart. These cities offer individuals suffering from cirrhosis access to cutting-edge clinical trials that may lead to improved treatment options.
Which are the top treatments for cirrhosis being explored in clinical trials?
Clinical trials exploring potential treatments for cirrhosis have identified two promising interventions. The Jumpstart Guide, introduced in 2023, is currently part of one active trial and represents a novel approach to tackling this condition. Similarly, the Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation procedure, first listed in 2022, has also garnered attention with one ongoing clinical trial dedicated to studying its effectiveness in cirrhosis treatment. These advancements offer hope for patients living with this challenging liver disease and may pave the way for improved outcomes in the future.
What are the most recent clinical trials for cirrhosis?
Exciting developments are unfolding in the field of cirrhosis treatment, with recent clinical trials offering promising avenues for patients. One noteworthy trial involves Seladelpar 10 mg, which has entered Phase 3 and shows potential for treating cirrhosis. Additionally, a Phase 2 study called Active demonstrates encouraging outcomes for this condition. Another trial, known as Arm 1, is progressing through both Phase 2 and Phase 3 stages and holds promise as well. Furthermore, a Phase 3 trial examines the benefits of adding lactulose to enhanced usual care in cirrhosis treatment. Lastly, Danazol Pill has shown promise in its early stages (Phase 2) as a potential therapy option for individuals affected by cirrhosis. These breakthroughs fuel optimism within the medical community as we strive towards improving outcomes for those battling this challenging disease.
What cirrhosis clinical trials were recently completed?
Several significant clinical trials in the field of cirrhosis have recently concluded, bringing hope for improved treatments. Stanford University completed a trial investigating Empagliflozin 10 MG in November 2021, while the University of Michigan explored the potential benefits of Lactulose during a trial that also finished that month. Georgetown University wrapped up their study on Proglumide in March 2021. These recent advancements highlight ongoing efforts to combat cirrhosis and provide valuable insights into potential therapeutic options for patients with this condition.